Comment on Patent Ruling

Cambridge Antibody Tech Group PLC
23 December 2001


Page 1 of 3


FOR IMMEDIATE RELEASE


07.00 GMT, 02.00 EST, Monday 24 December 2001






For Further Information Contact:



Cambridge Antibody Technology              Weber Shandwick Square Mile (Europe)
Tel: [phone]                   Tel: [phone]
David Chiswell, CEO                        Kevin Smith
John Aston, Finance Director               Graham Herring
Rowena Gardner, 
Head of Corporate Communications
                                           BMC Communications/The Trout
                                           Group (USA)  Tel: [phone]
                                           Brad Miles, ext 17 (media)
                                           Brandon Lewis, ext.15 (investors)





   CAMBRIDGE ANTIBODY TECHNOLOGY COMMENTS ON GRIFFITHS PATENT RULING OF 21
                                DECEMBER 2001



Melbourn, UK... Confirming his previous ruling in August this year, the
District Court Judge in Washington DC issued a ruling on 21 December 2001
indicating that he intends to rule that MorphoSys does not infringe Cambridge
Antibody Technology's Griffiths patent unless he is persuaded by 15 January
2002 that there is a genuine issue as to any material fact which would require
the matter to be retried before a jury. The Judge has given Cambridge Antibody
Technology (LSE: CAT; NASDAQ: CATG) until 15 January 2002 to file further
papers on this point, after which MorphoSys will have the chance to respond.
If the Judge issues the order then either party may appeal the decision.



In the previous ruling in August of this year the Judge found for CAT on four
of MorphoSys' five invalidity assertions. On their fifth assertion the Judge
ruled that the issue had to be decided by a jury. In that same ruling the
Judge indicated his view that MorphoSys should prevail on the question of
infringement.




Page 2 of 3

Dr. David Chiswell, CAT's CEO, commented: 'Although disappointed that the
judge has not accepted our arguments that MorphoSys' technology infringes the
Griffiths patent, we are pleased that his previous rulings have upheld
validity of the patent. We will comply with the Court's invitation to file
further arguments on the issue of infringement



This ruling has no effect on CAT's freedom to operate its technology or on the
separate actions relating to different patent families which CAT is bringing
against MorphoSys in Europe and the USA.



                                   - ENDS -



Notes to Editors:



Cambridge Antibody Technology (LSE: CAT; NASDAQ: CATG)

*         CAT is a UK biotechnology company using its proprietary technologies
in human monoclonal antibodies for drug discovery and drug development.  Based
in Melbourn, 10 miles south of Cambridge, England, CAT currently employs
around 260 people.

*         CAT is listed on the London Stock Exchange and on NASDAQ since June
2001. CAT raised £41m in its IPO in March 1997 and £93m in a secondary
offering in March 2000. m.

*         CAT has a world-leading platform technology for rapidly isolating
human monoclonal antibodies using phage display systems. CAT has extensive
phage antibody libraries, currently incorporating more than 100 billion
distinct antibodies. These libraries form the basis for the Company's strategy
to develop a portfolio of antibody-based drugs and to utilise antibodies as
tools for target validation.  Six human therapeutic antibodies developed by
CAT are at various stages of clinical trials.

*         CAT has alliances with a large number of biotechnology and
pharmaceutical companies to discover, develop and commercialise human
monoclonal antibody-based products. CAT has also licensed its proprietary
human antibody phage display libraries to several companies for target
validation and drug discovery. CAT's collaborators include: Abbott, AMRAD,
Elan, Eli Lilly, Genetics Institute, Genzyme, Human Genome Sciences, Immunex,
Incyte, Merck &Co., Inc, Oxford GlycoSciences, Pharmacia, Pfizer,
Wyeth-Ayerst, Xerion and Zyomyx.



CAT's Patent Portfolio



*         CAT's patent portfolio includes about 30 families of patents,
covering both technologies and products. CAT's core commercial technology is
covered by three main families of patents.

*         CAT and the MRC were awarded the US 'Griffiths' patent in March 1999
(the patent is co-owned).

*         The Griffiths patent relates to methods of isolating specific
antibodies to human self-antigens from phage display libraries and to
antibodies produced by these methods

*         In April 1999 MorphoSys filed a 'declaratory judgement action' in
the US District Court of Washington DC, asking the Court to declare that the
CAT's patent is invalid, and/or declare that it does not infringe the patent.
CAT counter-claimed against MorphoSys for infringement.  A Court hearing in
March 2001 was inconclusive; following this the Judge issued a ruling in
relation to various matters in August 2001.

*         Infringement litigation against MorphoSys is pending in the same
Court in respect of CAT's US 'McCafferty' patent, US 5,969, 108. A trial date
is currently set for April 2003.

*         Infringement litigation against MorphoSys is pending in the US, in
respect of CAT's 'Winter II' patent, granted on 19 June 2001 and in respect of
two Winter/Lerner/Huse patents granted on 18 September 2001 and licensed to
CAT.




Page 3 of 3



Application of the Safe Harbor of the Private Securities Litigation Reform Act
of 1995: This press release contains statements about Cambridge Antibody
Technology Group plc ('CAT') that are forward looking statements. All
statements other than statements of historical facts included in this press
release may be forward looking statements within the meaning of Section 21E of
the Securities Exchange Act of 1934. These forward looking statements are
based on numerous assumptions regarding CAT's present and future business
strategies and the environment in which CAT will operate in the future.
Certain factors that could cause CAT's actual results, performance or
achievements to differ materially from those in the forward looking statements
include: market conditions, CAT's ability to enter into and maintain
collaborative arrangements, success of product candidates in clinical trials,
regulatory developments and competition.